<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02420327</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00057097</org_study_id>
    <nct_id>NCT02420327</nct_id>
  </id_info>
  <brief_title>Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine</brief_title>
  <acronym>GalaNic</acronym>
  <official_title>The Use of Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test whether the attention-enhancing effects of low-dose nicotine
      can be enhanced by the drug galantamine, FDA-approved for the treatment of Alzheimer's
      disease. This proof-of-principle study is performed in healthy non-smokers and involves two
      single exposures to a nicotine patch (7 mg/24 hrs) and two single exposures to galantamine (4
      mg). The dose of galantamine is substantially lower than the clinical dose range of 16-24
      mg/day. The hypothesis is that performance-enhancing effects of nicotine are greater in the
      presence of this low dose of galantamine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy non-smokers will be screened for study eligibility and receive training on three
      different attention tasks. Over four test session, participants will then perform these tasks
      after receiving (1) a placebo patch and a placebo capsule, (2) a nicotine patch (7 mg/24 hrs)
      and a placebo capsule, (3) a placebo patch and a galantamine capsule, and (4) a nicotine
      patch and a galantamine capsule. The four test session are performed on separate days and
      take approximately 7 hours each. During the first 5 hours, the participant may read or watch
      TV while nicotine and/or galantamine are being absorbed. During the last two hours, the
      participant will perform the attention tasks on a computer. The investigators hypothesize
      that performance-enhancing effects of nicotine, which were documented in previous research,
      will be larger in the presence than in the absence of galantamine. This proof-of-concept
      would have implications for the development of drugs for the treatment of conditions such as
      Alzheimer's disease or schizophrenia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spatial Attentional Resource Allocation Task Predictive Trials Reaction Time</measure>
    <time_frame>45 min</time_frame>
    <description>The task requires detecting brief target stimuli presented at one of four locations in the four corner of the screen. On predictive trials, a central cue predicts the target location.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rapid Visual Information Processing Task Hit Rate</measure>
    <time_frame>30 min</time_frame>
    <description>The task requires following a stream of digits and detecting three consecutive odd or even numbers. The Hit Rate reflects the percentage of all target sequences that were detected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change Detection Task Accuracy</measure>
    <time_frame>15 min</time_frame>
    <description>The task requires encoding the color of 1 or 5 shape items and reporting whether or not one of the items changed color. Accuracy refers to the percentage of all trials in which a correct response was given.
One participant's data were excluded from this task because of excessive no-response trials.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spatial Attentional Resource Allocation Task (SARAT) Non-predictive Trial Reaction Time</measure>
    <time_frame>45 min</time_frame>
    <description>The task requires responding to brief target stimuli presented randomly in one of four locations in the four corners of the screen. On non-predictive trial, the cue does not provide any advance information about where the target will occur.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rapid Visual Information Processing Task Reaction Time</measure>
    <time_frame>30 min</time_frame>
    <description>The task requires the detection of three consecutive odd or three consecutive even digits in a stream of sequentially presented digits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change Detection Task Reaction Time</measure>
    <time_frame>15 min</time_frame>
    <description>The task requires encoding the color of 1 or 5 shape items and reporting whether or not one of the items changed color.
One participant's data were excluded from this task because of excessive no-response trials.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profile of Mood Scale - Total Mood Disturbance</measure>
    <time_frame>5 min</time_frame>
    <description>Participants rate their current subjective state on a list of adjectives, which contribute to six factors/subscales. &quot;Total Mood Disturbance&quot; is a composite measure, obtained by summing the scores of all subscales, each with a range of 0-4, weighting the one positively valenced factor negatively. Thus, smaller or more negative values represent a more positive mood state. The theoretical range of the &quot;Total Mood Disturbance&quot; measure is from -4 to +20.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Basic Science Study of the Mechanisms of Attentional Enhancement by Compounds Acting on the Nicotinic Receptor</condition>
  <arm_group>
    <arm_group_label>Placebo patch and placebo capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the double-placebo test day, participants receive a placebo patch and a placebo capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine patch and placebo capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the nicotine test day, participants receive a nicotine patch (7 mg/24 hrs) and a placebo capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo patch and galantamine capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the galantamine test day, participants receive a placebo patch and a capsule containing 4 mg of galantamine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine patch and galantamine capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the nicotine + galantamine test day, participants receive a nicotine patch (7 mg/24 hrs) and a capsule containing 4 mg of galantamine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo patch &amp; placebo capsule</intervention_name>
    <description>On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.</description>
    <arm_group_label>Placebo patch and placebo capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo patch &amp; galantamine capsule</intervention_name>
    <description>On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).</description>
    <arm_group_label>Placebo patch and galantamine capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine patch &amp; placebo capsule</intervention_name>
    <description>On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.</description>
    <arm_group_label>Nicotine patch and placebo capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine patch and galantamine capsule</intervention_name>
    <description>On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).</description>
    <arm_group_label>Nicotine patch and galantamine capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 21 to 55 years.

          -  No exposure to any nicotine-containing product in the last year.

          -  Smoked no more that 40 cigarettes, cigars or cigarillos in lifetime.

          -  Normal or corrected to normal vision (at least 20/80).

          -  Body weight 110-220 lbs.

        Exclusion Criteria:

          -  Pregnant or breast-feeding.

          -  Drug or alcohol abuse or dependence currently or in the last 2 years.

          -  DSM Axis I mood, anxiety or psychotic disorder.

          -  Cardiovascular or cerebrovascular disease, such as history of myocardial infarction
             and ischemia, heart failure, angina, stroke, severe arrhythmias, or EKG abnormalities
             (Wolf-Parkinson-White syndrome, Complete left bundle branch block, PR interval &lt;120 ms
             or &gt;200 ms, Prolonged QT interval (corrected) &gt;500 ms, Cardiac arrhythmias as defined
             by PACs &gt;3 per min or PVCs &gt;1 per min).

          -  Uncontrolled hypertension (resting systolic BP above 140 or diastolic above 90 mm Hg).

          -  Hypotension (resting systolic BP below 90 or diastolic below 60).

          -  Significant kidney or liver impairment.

          -  Moderate to severe asthma.

          -  Obstructive pulmonary disease.

          -  Type I or II diabetes.

          -  Use of any centrally active medications; any peripherally acting cholinergic
             medications; cimetidine; ketoconazole; erythromycin; quinidine, or chronic
             nonsteroidal anti-inflammatory drugs.

          -  History of or current neurological illnesses, such as stroke, seizure disorders,
             neurodegenerative diseases, or organic brain syndrome.

          -  Learning disability, mental retardation, or any other condition that impedes
             cognition.

          -  Heart rate &lt;55 bpm.

          -  Current or history of gastric ulcer disease.

          -  Any surgeries requiring full anesthesia scheduled within 2 weeks of any of the study
             test sessions.

          -  Anemia.

          -  Inability to perform the Rapid Visual Information Processing Task.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Britta Hahn, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland School of Medicine, Maryland Psychiatric Research Center</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>April 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2015</study_first_posted>
  <results_first_submitted>July 3, 2018</results_first_submitted>
  <results_first_submitted_qc>August 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 17, 2018</results_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Britta Hahn</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>nicotine</keyword>
  <keyword>galantamine</keyword>
  <keyword>attention</keyword>
  <keyword>cognition</keyword>
  <keyword>non-smoker</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Galantamine</mesh_term>
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02420327/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Adults</title>
          <description>All participants receive the following four interventions, on separate days, in a counterbalanced order:
placebo patch and placebo capsule
placebo patch and galantamine capsule
nicotine patch and placebo capsule
nicotine patch and galantamine capsule
Placebo patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.
Placebo patch &amp; galantamine capsule: On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).
Nicotine patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.
Nicotine patch and galantamine capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This includes 27 study completers and 16 study non-completers.</population>
      <group_list>
        <group group_id="B1">
          <title>Healthy Adults</title>
          <description>All participants receive the following four interventions, on separate days, in a counterbalanced order:
placebo patch and placebo capsule
placebo patch and galantamine capsule
nicotine patch and placebo capsule
nicotine patch and galantamine capsule
Placebo patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.
Placebo patch &amp; galantamine capsule: On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).
Nicotine patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.
Nicotine patch and galantamine capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Spatial Attentional Resource Allocation Task Predictive Trials Reaction Time</title>
        <description>The task requires detecting brief target stimuli presented at one of four locations in the four corner of the screen. On predictive trials, a central cue predicts the target location.</description>
        <time_frame>45 min</time_frame>
        <population>27 healthy adult non-smokers</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Patch and Placebo Capsule</title>
            <description>On the double-placebo test day, participants receive a placebo patch and a placebo capsule.
Placebo patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Patch and Placebo Capsule</title>
            <description>On the nicotine test day, participants receive a nicotine patch (7 mg/24 hrs) and a placebo capsule.
Nicotine patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Patch and Galantamine Capsule</title>
            <description>On the galantamine test day, participants receive a placebo patch and a capsule containing 4 mg of galantamine.
Placebo patch &amp; galantamine capsule: On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).</description>
          </group>
          <group group_id="O4">
            <title>Nicotine Patch and Galantamine Capsule</title>
            <description>On the nicotine + galantamine test day, participants receive a nicotine patch (7 mg/24 hrs) and a capsule containing 4 mg of galantamine.
Nicotine patch and galantamine capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).</description>
          </group>
        </group_list>
        <measure>
          <title>Spatial Attentional Resource Allocation Task Predictive Trials Reaction Time</title>
          <description>The task requires detecting brief target stimuli presented at one of four locations in the four corner of the screen. On predictive trials, a central cue predicts the target location.</description>
          <population>27 healthy adult non-smokers</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="420" spread="66"/>
                    <measurement group_id="O2" value="408" spread="56"/>
                    <measurement group_id="O3" value="416" spread="61"/>
                    <measurement group_id="O4" value="413" spread="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rapid Visual Information Processing Task Hit Rate</title>
        <description>The task requires following a stream of digits and detecting three consecutive odd or even numbers. The Hit Rate reflects the percentage of all target sequences that were detected.</description>
        <time_frame>30 min</time_frame>
        <population>Healthy adult non-smokers</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Patch and Placebo Capsule</title>
            <description>On the double-placebo test day, participants receive a placebo patch and a placebo capsule.
Placebo patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Patch and Placebo Capsule</title>
            <description>On the nicotine test day, participants receive a nicotine patch (7 mg/24 hrs) and a placebo capsule.
Nicotine patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Patch and Galantamine Capsule</title>
            <description>On the galantamine test day, participants receive a placebo patch and a capsule containing 4 mg of galantamine.
Placebo patch &amp; galantamine capsule: On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).</description>
          </group>
          <group group_id="O4">
            <title>Nicotine Patch and Galantamine Capsule</title>
            <description>On the nicotine + galantamine test day, participants receive a nicotine patch (7 mg/24 hrs) and a capsule containing 4 mg of galantamine.
Nicotine patch and galantamine capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).</description>
          </group>
        </group_list>
        <measure>
          <title>Rapid Visual Information Processing Task Hit Rate</title>
          <description>The task requires following a stream of digits and detecting three consecutive odd or even numbers. The Hit Rate reflects the percentage of all target sequences that were detected.</description>
          <population>Healthy adult non-smokers</population>
          <units>percentage of all targets</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" spread="19"/>
                    <measurement group_id="O2" value="54" spread="18"/>
                    <measurement group_id="O3" value="49" spread="21"/>
                    <measurement group_id="O4" value="54" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change Detection Task Accuracy</title>
        <description>The task requires encoding the color of 1 or 5 shape items and reporting whether or not one of the items changed color. Accuracy refers to the percentage of all trials in which a correct response was given.
One participant's data were excluded from this task because of excessive no-response trials.</description>
        <time_frame>15 min</time_frame>
        <population>Healthy adult non-smokers</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Patch and Placebo Capsule</title>
            <description>On the double-placebo test day, participants receive a placebo patch and a placebo capsule.
Placebo patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Patch and Placebo Capsule</title>
            <description>On the nicotine test day, participants receive a nicotine patch (7 mg/24 hrs) and a placebo capsule.
Nicotine patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Patch and Galantamine Capsule</title>
            <description>On the galantamine test day, participants receive a placebo patch and a capsule containing 4 mg of galantamine.
Placebo patch &amp; galantamine capsule: On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).</description>
          </group>
          <group group_id="O4">
            <title>Nicotine Patch and Galantamine Capsule</title>
            <description>On the nicotine + galantamine test day, participants receive a nicotine patch (7 mg/24 hrs) and a capsule containing 4 mg of galantamine.
Nicotine patch and galantamine capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).</description>
          </group>
        </group_list>
        <measure>
          <title>Change Detection Task Accuracy</title>
          <description>The task requires encoding the color of 1 or 5 shape items and reporting whether or not one of the items changed color. Accuracy refers to the percentage of all trials in which a correct response was given.
One participant's data were excluded from this task because of excessive no-response trials.</description>
          <population>Healthy adult non-smokers</population>
          <units>percentage of all trials</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" spread="6"/>
                    <measurement group_id="O2" value="83" spread="6"/>
                    <measurement group_id="O3" value="84" spread="6"/>
                    <measurement group_id="O4" value="84" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Spatial Attentional Resource Allocation Task (SARAT) Non-predictive Trial Reaction Time</title>
        <description>The task requires responding to brief target stimuli presented randomly in one of four locations in the four corners of the screen. On non-predictive trial, the cue does not provide any advance information about where the target will occur.</description>
        <time_frame>45 min</time_frame>
        <population>Healthy adult non-smokers</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Patch and Placebo Capsule</title>
            <description>On the double-placebo test day, participants receive a placebo patch and a placebo capsule.
Placebo patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Patch and Placebo Capsule</title>
            <description>On the nicotine test day, participants receive a nicotine patch (7 mg/24 hrs) and a placebo capsule.
Nicotine patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Patch and Galantamine Capsule</title>
            <description>On the galantamine test day, participants receive a placebo patch and a capsule containing 4 mg of galantamine.
Placebo patch &amp; galantamine capsule: On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).</description>
          </group>
          <group group_id="O4">
            <title>Nicotine Patch and Galantamine Capsule</title>
            <description>On the nicotine + galantamine test day, participants receive a nicotine patch (7 mg/24 hrs) and a capsule containing 4 mg of galantamine.
Nicotine patch and galantamine capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).</description>
          </group>
        </group_list>
        <measure>
          <title>Spatial Attentional Resource Allocation Task (SARAT) Non-predictive Trial Reaction Time</title>
          <description>The task requires responding to brief target stimuli presented randomly in one of four locations in the four corners of the screen. On non-predictive trial, the cue does not provide any advance information about where the target will occur.</description>
          <population>Healthy adult non-smokers</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="472" spread="71"/>
                    <measurement group_id="O2" value="455" spread="62"/>
                    <measurement group_id="O3" value="465" spread="66"/>
                    <measurement group_id="O4" value="449" spread="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rapid Visual Information Processing Task Reaction Time</title>
        <description>The task requires the detection of three consecutive odd or three consecutive even digits in a stream of sequentially presented digits.</description>
        <time_frame>30 min</time_frame>
        <population>Healthy adult non-smokers</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Patch and Placebo Capsule</title>
            <description>On the double-placebo test day, participants receive a placebo patch and a placebo capsule.
Placebo patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Patch and Placebo Capsule</title>
            <description>On the nicotine test day, participants receive a nicotine patch (7 mg/24 hrs) and a placebo capsule.
Nicotine patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Patch and Galantamine Capsule</title>
            <description>On the galantamine test day, participants receive a placebo patch and a capsule containing 4 mg of galantamine.
Placebo patch &amp; galantamine capsule: On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).</description>
          </group>
          <group group_id="O4">
            <title>Nicotine Patch and Galantamine Capsule</title>
            <description>On the nicotine + galantamine test day, participants receive a nicotine patch (7 mg/24 hrs) and a capsule containing 4 mg of galantamine.
Nicotine patch and galantamine capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).</description>
          </group>
        </group_list>
        <measure>
          <title>Rapid Visual Information Processing Task Reaction Time</title>
          <description>The task requires the detection of three consecutive odd or three consecutive even digits in a stream of sequentially presented digits.</description>
          <population>Healthy adult non-smokers</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="463" spread="59"/>
                    <measurement group_id="O2" value="459" spread="64"/>
                    <measurement group_id="O3" value="473" spread="70"/>
                    <measurement group_id="O4" value="459" spread="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change Detection Task Reaction Time</title>
        <description>The task requires encoding the color of 1 or 5 shape items and reporting whether or not one of the items changed color.
One participant's data were excluded from this task because of excessive no-response trials.</description>
        <time_frame>15 min</time_frame>
        <population>Healthy adult non-smokers</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Patch and Placebo Capsule</title>
            <description>On the double-placebo test day, participants receive a placebo patch and a placebo capsule.
Placebo patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Patch and Placebo Capsule</title>
            <description>On the nicotine test day, participants receive a nicotine patch (7 mg/24 hrs) and a placebo capsule.
Nicotine patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Patch and Galantamine Capsule</title>
            <description>On the galantamine test day, participants receive a placebo patch and a capsule containing 4 mg of galantamine.
Placebo patch &amp; galantamine capsule: On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).</description>
          </group>
          <group group_id="O4">
            <title>Nicotine Patch and Galantamine Capsule</title>
            <description>On the nicotine + galantamine test day, participants receive a nicotine patch (7 mg/24 hrs) and a capsule containing 4 mg of galantamine.
Nicotine patch and galantamine capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).</description>
          </group>
        </group_list>
        <measure>
          <title>Change Detection Task Reaction Time</title>
          <description>The task requires encoding the color of 1 or 5 shape items and reporting whether or not one of the items changed color.
One participant's data were excluded from this task because of excessive no-response trials.</description>
          <population>Healthy adult non-smokers</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1018" spread="241"/>
                    <measurement group_id="O2" value="1023" spread="216"/>
                    <measurement group_id="O3" value="1043" spread="239"/>
                    <measurement group_id="O4" value="973" spread="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Profile of Mood Scale - Total Mood Disturbance</title>
        <description>Participants rate their current subjective state on a list of adjectives, which contribute to six factors/subscales. &quot;Total Mood Disturbance&quot; is a composite measure, obtained by summing the scores of all subscales, each with a range of 0-4, weighting the one positively valenced factor negatively. Thus, smaller or more negative values represent a more positive mood state. The theoretical range of the &quot;Total Mood Disturbance&quot; measure is from -4 to +20.</description>
        <time_frame>5 min</time_frame>
        <population>Healthy adult non-smokers</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Patch and Placebo Capsule</title>
            <description>On the double-placebo test day, participants receive a placebo patch and a placebo capsule.
Placebo patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Patch and Placebo Capsule</title>
            <description>On the nicotine test day, participants receive a nicotine patch (7 mg/24 hrs) and a placebo capsule.
Nicotine patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Patch and Galantamine Capsule</title>
            <description>On the galantamine test day, participants receive a placebo patch and a capsule containing 4 mg of galantamine.
Placebo patch &amp; galantamine capsule: On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).</description>
          </group>
          <group group_id="O4">
            <title>Nicotine Patch and Galantamine Capsule</title>
            <description>On the nicotine + galantamine test day, participants receive a nicotine patch (7 mg/24 hrs) and a capsule containing 4 mg of galantamine.
Nicotine patch and galantamine capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).</description>
          </group>
        </group_list>
        <measure>
          <title>Profile of Mood Scale - Total Mood Disturbance</title>
          <description>Participants rate their current subjective state on a list of adjectives, which contribute to six factors/subscales. &quot;Total Mood Disturbance&quot; is a composite measure, obtained by summing the scores of all subscales, each with a range of 0-4, weighting the one positively valenced factor negatively. Thus, smaller or more negative values represent a more positive mood state. The theoretical range of the &quot;Total Mood Disturbance&quot; measure is from -4 to +20.</description>
          <population>Healthy adult non-smokers</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.91"/>
                    <measurement group_id="O2" value="-0.48" spread="0.98"/>
                    <measurement group_id="O3" value="-0.60" spread="0.99"/>
                    <measurement group_id="O4" value="-0.43" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During each of the four test sessions (7 hours each).</time_frame>
      <desc>Participants had vital signs taken and completed a side-effects checklist hourly (after patch) or every thirty minutes (after capsule). Unsolicited reports of adverse effects were also recorded.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Patch and Placebo Capsule</title>
          <description>On the double-placebo test day, participants receive a placebo patch and a placebo capsule.
Placebo patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.</description>
        </group>
        <group group_id="E2">
          <title>Nicotine Patch and Placebo Capsule</title>
          <description>On the nicotine test day, participants receive a nicotine patch (7 mg/24 hrs) and a placebo capsule.
Nicotine patch &amp; placebo capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.</description>
        </group>
        <group group_id="E3">
          <title>Placebo Patch and Galantamine Capsule</title>
          <description>On the galantamine test day, participants receive a placebo patch and a capsule containing 4 mg of galantamine.
Placebo patch &amp; galantamine capsule: On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).</description>
        </group>
        <group group_id="E4">
          <title>Nicotine Patch and Galantamine Capsule</title>
          <description>On the nicotine + galantamine test day, participants receive a nicotine patch (7 mg/24 hrs) and a capsule containing 4 mg of galantamine.
Nicotine patch and galantamine capsule: On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>palpitations</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pain at patch site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Britta Hahn</name_or_title>
      <organization>University of Maryland School of Medicine</organization>
      <phone>410-402-6112</phone>
      <email>bhahn@som.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

